COMMUNIQUÉS West-GlobeNewswire

Medicovestor Announces FDA IND Clearance for MC001, Advancing to An International Phase 1 Study
05/10/2026
NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Medicovestor, Inc. today announced FDA clearance of its Investigational New Drug (IND) application for MC001, the Company's first-in-class dimeric chemoimmunotherapy ADC for [...]
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
05/10/2026
– ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction – SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company [...]
Research Peptide Companies: Kylo Peptides Scores 96.7/100 in Plastic Surgery Key Review
05/10/2026
Sheridan, Wyoming, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides https://kylopeptides.com/ [], a U.S.-based supplier of research-use-only peptides, has received a score of 96.7/100 in a Plastic Surgery Key review of [...]
Transactions under Novonesis’ share buyback program
05/10/2026
Please read the announcement in PDF Attachment 2026_20_Share_buyback
Alpha Tau to Participate in October Investor Conferences
05/10/2026
JERUSALEM, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced [...]
Human Appeal Celebrates Top UK Volunteers at Third Annual Purple Legacy Awards
05/10/2026
MANCHESTER, United Kingdom, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Leading Humanitarian charity Human Appeal brought together 150 volunteers, staff and guests from London, the Midlands, the North and Scotland in Manchester [...]
AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential
05/10/2026
OCALA, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media coverage of the antiviral potential of Ampligen ® (rintatolimod), the [...]
Beacon Therapeutics Named a “Fierce 15” Company by Fierce Biotech
05/10/2026
LONDON and CAMBRIDGE, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics, a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular [...]
Cerevance Appoints Karl Kieburtz, M.D., M.P.H., as Chief Medical Officer
05/10/2026
Appointment solidifies Cerevance’s leadership team as the company advances solengepras through Phase 3 development in Parkinson’s disease BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage [...]
OnCusp Therapeutics Announces Positive Phase 1b Data Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Resistant Ovarian Cancer (PROC) Presented at Plenary Oral Session of the IGCS 2026 Annual Global Meeting
05/10/2026
Initial Phase 1b data highlight promising clinical activity in patients with PROC and support continued clinical development of CUSP06 At the September 23, 2026, data cutoff, CUSP06 achieved a 62% objective response [...]
Forward Therapeutics Announces Positive Phase 1 Data for Potential Best-in-Class Oral TNFR1 Signaling Inhibitor FT2109, Supporting Advancement into Phase 2 Development
05/10/2026
BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Forward Therapeutics, Inc. (“Forward” or the “Company”), a clinical-stage biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today [...]
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement
05/10/2026
MALVERN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
05/10/2026
-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation in ATP7B, the [...]
Cannara étend son entente d’approvisionnement international avec Curaleaf
05/10/2026
MONTRÉAL, 05 oct. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la « Société », « nous » ou « notre ») ( TSX : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), un producteur verticalement intégré de [...]
AID FOR AIDS and AID FOR LIFE to Celebrate 30 Years of Global Humanitarian Impact at My Hero Gala in New York
05/10/2026
“Dignity Across Borders” Gala Will Honor Edgar Ramírez, Nathalie Rayes, Maria Eugenia Maury and Mary Ann Torres, While Raising Critical Funds for HIV Treatment, Migrant Integration and Earthquake Recovery in Venezuela [...]
Zenflow Secures $52M Series D Financing and Announces Exclusive U.S. Distribution Partnership with Cook Medical
05/10/2026
Series D proceeds to support commercialization of the Zenflow Spring® System for Men with Enlarged Prostate SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Zenflow, Inc., developer of the Zenflow Spring® [...]
Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform
05/10/2026
A new patent application covers Polyrizon’s proprietary mucoadhesive platform and its potential applications in nasal drug delivery. Raanana, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the [...]
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
05/10/2026
Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to initiate in the fourth [...]
BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels
05/10/2026
- In exploratory analyses at Month 12, among individuals with LGMD2I/R9 (FKRP-related) with elevated HS troponin I at baseline, 100% treated with BBP-418 returned to the normal range by Month 12 versus 40% in the [...]

Pages